{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T22:50:41Z","timestamp":1792450241561,"version":"4.5.0"},"reference-count":20,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Otolaryngol Head Neck Surg"],"published-print":{"date-parts":[[2022,10,1]]},"abstract":"<jats:sec id=\"ab-ooi220048-4\"><jats:title>Importance<\/jats:title><jats:p>Pembrolizumab, a monoclonal antibody targeting programmed cell death 1, is currently approved by the US Food and Drug Administration for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). The potential neoadjuvant role of programmed cell death 1 inhibitors in primary surgical management of HNSCC and effects on surgical outcomes are poorly understood.<\/jats:p><\/jats:sec><jats:sec id=\"ab-ooi220048-5\"><jats:title>Objective<\/jats:title><jats:p>To evaluate the incidence of postoperative adverse events in treatment-naive patients with advanced oral cavity cancer receiving neoadjuvant pembrolizumab when compared with matched controls, as part of a window-of-opportunity multi-institutional clinical trial assessing neoadjuvant pembrolizumab for locally advanced HNSCC.<\/jats:p><\/jats:sec><jats:sec id=\"ab-ooi220048-6\"><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>This retrospective cohort study at a single tertiary academic institution included treatment-naive patients with local regionally advanced oral cavity squamous cell carcinoma (OCSCC) who were undergoing surgical resection.<\/jats:p><\/jats:sec><jats:sec id=\"ab-ooi220048-7\"><jats:title>Exposures<\/jats:title><jats:p>Patients with local regionally advanced resectable OCSCC who received neoadjuvant pembrolizumab were retrospectively reviewed for postoperative adverse events. Controls were matched by age, race, smoking status, and overall cancer stage based on historical data at the same institution. Matched-cohort analysis was performed using a McNemar test to assess differences between the groups.<\/jats:p><\/jats:sec><jats:sec id=\"ab-ooi220048-8\"><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>Incidence of adverse events following surgical resection of advanced OCSCC within 30 days of surgery and on continued follow-up.<\/jats:p><\/jats:sec><jats:sec id=\"ab-ooi220048-9\"><jats:title>Results<\/jats:title><jats:p>A total of 64 patients (32 as part of the prospective clinical trial and 32 as controls; mean [SD] age, 59.6 [10.3] years; 28 [44%] women) were included in the analysis. Postoperative adverse events in the 32 patients receiving pembrolizumab included lymphedema (n\u2009=\u200920 [63%]), trismus (n\u2009=\u20097 [22%]), return to operating room (n\u2009=\u20097 [22%]), wound infection (n\u2009=\u20097 [22%]), fistula (n\u2009=\u20096 [19%]), wound dehiscence (n\u2009=\u20094 [13%]), flap failure (n\u2009=\u20093 [9%]), and hematoma (n\u2009=\u20092 [6%]). The matched control group demonstrated similar complication rates without considerable differences, except for trismus (n\u2009=\u200916 [50%]), which was greater by a difference of 28.1% (95% CI, 5.6%-50.6%) in the control group.<\/jats:p><\/jats:sec><jats:sec id=\"ab-ooi220048-10\"><jats:title>Conclusions and Relevance<\/jats:title><jats:p>This cohort study examined surgical complications among patients with local regionally advanced OCSCC treated with neoadjuvant pembrolizumab and found that serious adverse events were similar to those in patients who underwent standard-of-care treatment. This suggests that there is no increased perioperative morbidity in the use of preoperative treatment with immunotherapy. Further prospective studies are needed to validate these findings for oral cavity cancer and other subsites of the head and neck.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamaoto.2022.2291","type":"journal-article","created":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T15:02:07Z","timestamp":1661439727000},"page":"935","source":"Crossref","is-referenced-by-count":29,"title":["Association of Neoadjuvant Pembrolizumab for Oral Cavity Squamous Cell Carcinoma With Adverse Events After Surgery in Treatment-Naive Patients"],"prefix":"10.1001","volume":"148","author":[{"given":"Alice L.","family":"Tang","sequence":"first","affiliation":[{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, University of Cincinnati College of Medicine, Cincinnati, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"O\u2019Neil","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, University of Cincinnati College of Medicine, Cincinnati, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"McDermott","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, University of Cincinnati College of Medicine, Cincinnati, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siddhant","family":"Tripathi","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, University of Cincinnati College of Medicine, Cincinnati, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raisa","family":"Tikhtman","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, University of Cincinnati College of Medicine, Cincinnati, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan R.","family":"Mark","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, Eastern Virginia Medical School, Norfolk"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yash","family":"Patil","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, University of Cincinnati College of Medicine, Cincinnati, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meredith","family":"Tabangin","sequence":"additional","affiliation":[{"name":"Division of Biostatistics and Epidemiology, Cincinnati Children\u2019s Hospital, Cincinnati, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mekibib","family":"Altaye","sequence":"additional","affiliation":[{"name":"Division of Biostatistics and Epidemiology, Cincinnati Children\u2019s Hospital, Cincinnati, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trisha M.","family":"Wise-Draper","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chad A.","family":"Zender","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, University of Cincinnati College of Medicine, Cincinnati, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"19","key":"ooi220048r1","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1056\/NEJMoa032641","article-title":"Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer.","volume":"350","author":"Bernier","year":"2004","journal-title":"N Engl J Med"},{"issue":"3","key":"ooi220048r2","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s10147-014-0689-z","article-title":"Current status of oral cancer treatment strategies: surgical treatments for oral squamous cell carcinoma.","volume":"19","author":"Omura","year":"2014","journal-title":"Int J Clin Oncol"},{"issue":"3","key":"ooi220048r3","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.v71.3","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"7","key":"ooi220048r4","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1158\/1078-0432.CCR-21-3351","article-title":"Phase II clinical trial of neoadjuvant and adjuvant pembrolizumab in resectable local-regionally advanced head and neck squamous cell carcinoma.","volume":"28","author":"Wise-Draper","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"19","key":"ooi220048r5","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for recurrent squamous-cell carcinoma of the head and neck.","volume":"375","author":"Ferris","year":"2016","journal-title":"N Engl J Med"},{"key":"ooi220048r6","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1146\/immunol.2008.26.issue-1","article-title":"PD-1 and its ligands in tolerance and immunity.","volume":"26","author":"Keir","year":"2008","journal-title":"Annu Rev Immunol"},{"issue":"11","key":"ooi220048r7","doi-asserted-by":"publisher","first-page":"2777","DOI":"10.1080\/21645515.2016.1199310","article-title":"Pembrolizumab (Keytruda).","volume":"12","author":"Kwok","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"ooi220048r8","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.oraloncology.2018.04.008","article-title":"Nivolumab vs investigator\u2019s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression.","volume":"81","author":"Ferris","year":"2018","journal-title":"Oral Oncol"},{"issue":"17","key":"ooi220048r9","doi-asserted-by":"publisher","first-page":"5221","DOI":"10.1158\/1078-0432.CCR-18-3944","article-title":"Nivolumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: efficacy and safety in CheckMate 141 by prior cetuximab use.","volume":"25","author":"Ferris","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"7","key":"ooi220048r10","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/S1470-2045(16)30066-3","article-title":"Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial.","volume":"17","author":"Seiwert","year":"2016","journal-title":"Lancet Oncol"},{"key":"ooi220048r11","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2022.105815","article-title":"Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: health-related quality-of-life results from KEYNOTE-048.","volume":"128","author":"Rischin","year":"2022","journal-title":"Oral Oncol"},{"issue":"5","key":"ooi220048r12","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1002\/hed.v43.5","article-title":"Examining the relationship of immunotherapy and wound complications following flap reconstruction in patients with head and neck cancer.","volume":"43","author":"Mays","year":"2021","journal-title":"Head Neck"},{"key":"ooi220048r13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.848881","article-title":"Perioperative outcomes of minimally invasive esophagectomy after neoadjuvant immunotherapy for patients with locally advanced esophageal squamous cell carcinoma.","volume":"13","author":"Cheng","year":"2022","journal-title":"Front Immunol"},{"issue":"3","key":"ooi220048r14","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1016\/j.jtcvs.2020.11.106","article-title":"Safety and feasibility of esophagectomy following combined immunotherapy and chemoradiotherapy for esophageal cancer.","volume":"161","author":"Sihag","year":"2021","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"2","key":"ooi220048r15","doi-asserted-by":"publisher","first-page":"333","DOI":"10.21037\/jtd","article-title":"Immune checkpoint inhibitors in neoadjuvant therapy of non-small cell lung cancer: a systematic review and meta-analysis.","volume":"14","author":"Ge","year":"2022","journal-title":"J Thorac Dis"},{"issue":"5","key":"ooi220048r16","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1158\/1078-0432.CCR-21-1816","article-title":"Tadalafil enhances immune signatures in response to neoadjuvant nivolumab in resectable head and neck squamous cell carcinoma.","volume":"28","author":"Luginbuhl","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"19","key":"ooi220048r17","doi-asserted-by":"publisher","first-page":"5140","DOI":"10.1158\/1078-0432.CCR-20-1695","article-title":"Neoadjuvant and adjuvant pembrolizumab in resectable locally advanced, human papillomavirus-unrelated head and neck cancer: a multicenter, phase II trial.","volume":"26","author":"Uppaluri","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"4","key":"ooi220048r18","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1007\/s00268-019-05314-2","article-title":"Perioperative outcomes of melanoma patients undergoing surgery after receiving immunotherapy or targeted therapy.","volume":"44","author":"Sun","year":"2020","journal-title":"World J Surg"},{"issue":"7","key":"ooi220048r19","doi-asserted-by":"publisher","first-page":"2695","DOI":"10.1007\/s00405-017-4519-6","article-title":"Trismus following different treatment modalities for head and neck cancer: a systematic review of subjective measures.","volume":"274","author":"Loh","year":"2017","journal-title":"Eur Arch Otorhinolaryngol"},{"issue":"8","key":"ooi220048r20","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.31557\/APJCP.2021.22.8.2437","article-title":"Prevalence of trismus and its impact on oral health-related quality of life in patients treated for oral squamous cell carcinoma.","volume":"22","author":"Gondivkar","year":"2021","journal-title":"Asian Pac J Cancer Prev"}],"container-title":["JAMA Otolaryngology\u2013Head &amp; Neck Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaotolaryngology\/articlepdf\/2795628\/jamaotolaryngology_tang_2022_oi_220048_1664995492.96313.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,13]],"date-time":"2022-10-13T15:24:43Z","timestamp":1665674683000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaotolaryngology\/fullarticle\/2795628"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,1]]},"references-count":20,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoto.2022.2291","relation":{},"ISSN":["2168-6181"],"issn-type":[{"value":"2168-6181","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10,1]]}}}